J.P. Morgan 43rd Annual Healthcare Conference 2025
13-16 January 2025
San Francisco, USA
Tim Sharpington and Mat Robinson attending
Building a clinical-stage biopharmaceutical company supported by leaders in precision microbiome science and medicine, and a strong syndicate of investors.
Advancing our pipeline of clinic-ready defined live biotherapeutic products, with known mechanisms of action, for immuno-oncology and inflammatory bowel disease.
Leveraging our clinic-led discovery platform to enable precise identification of bacteria linked to patient outcomes and targeting of specific patient populations.
J.P. Morgan 43rd Annual Healthcare Conference 2025
13-16 January 2025
San Francisco, USA
Tim Sharpington and Mat Robinson attending
Microbiotica is a clinic-ready biopharmaceutical company developing a pipeline of orally-delivered live biotherapeutic products (LBPs) composed of highly-defined bacterial strains for therapeutic applications in immuno-oncology (IO) and inflammatory bowel disease (IBD).